Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Passiflora Extract for Benzodiazepine Withdrawal
NCT03780595Phase 4Unknown
- Sponsor
- Nutrición Médica
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of Sedistress in benzodiazepine withdrawal syndrome (BWS) (2 arms), sponsored by Nutrición Médica. Primary endpoint: Percentage of patients with >= 50% reduction in benzodiazepine dose at 10 weeks. Status: unknown.
02
Drugs
Sedistress
03
Conditions
benzodiazepine withdrawal syndrome (BWS)
Beyond the preview
Go deeper on NCT03780595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780595.